Adlai Nortye Ltd. (ANL) Stock Score, Valuation & Financial Research

Adlai Nortye Ltd. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ANL

Adlai Nortye Ltd. does not currently have a complete Wall Street Score. The stored market price is USD 14.46. These figures are a research snapshot, not a buy or sell recommendation.

What Adlai Nortye Ltd. does

Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas. The company's pipeline also features AN0025, a small molecule prostaglandin E receptor 4 antagonist designed to modulate the tumor microenvironment. This candidate is in Phase Ib clinical trials, exploring its efficacy in treating various conditions, including: recurrent non-small cell lung cancer; urothelial cancer (post-anti-PD-1/PD-L1 treatments); recurrent triple-negative breast cancer; microsatellite stable colorectal cancer; and cervical cancer (following standard-of-care treatments). Additionally, ANL is developing AN4005, an oral small-molecule PD-L1 inhibitor. This drug, which is in Phase I clinical trials, aims to induce and stabilize PD-L1 dimerization to disrupt the interaction between PD-1 and PD-L1. Beyond their clinical programs, Adlai Nortye has early-stage research candidates such as AN8025, a multifunctional antibody that acts as a modulator of T cells and antigen-presenting cells, and AN9025, an oral small molecule pan-KRAS inhibitor. Established in 2004, the company's headquarters are situated in Grand Cayman, Cayman Islands.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Adlai Nortye is a clinical-stage biotechnology company that does not yet generate commercial revenue. Its business model focuses on the research and development of innovative cancer therapies, funded primarily through equity financing and strategic licensing collaborations.

Products and services

  • The company is developing a pipeline of oncology drug candidates, including AN9025 (a pan-RAS(ON) inhibitor) and other therapeutic assets targeting solid tumors.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company utilizes various unnamed third-party CROs to conduct clinical trials and preclinical research. Source

Business relationships and partnerships

  • Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm) — A license agreement for the development of AN9025, where Adlai Nortye retains ex-China rights and ASK Pharm holds rights in mainland China, Hong Kong, and Macao. Source

Business strengths to evaluate

  • Dual R&D presence in the U.S. and China Source

Business risks and research considerations

  • History of operating losses and dependence on external financing Source
  • Clinical trial failure and regulatory approval uncertainty Source

Sources: Company research source · Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm) · Dual R&D presence in the U.S. and China

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ANL financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 14.46
Market capitalization:
767.54M (currency not supplied)
Revenue:
USD 19.68M
Net income:
USD -22.53M
Free cash flow:
USD -33.73M
Cash:
USD 132.59M
Total debt:
USD 26.7M
EPS:
USD -1.96

What stands out

  • Free cash flow is USD -33.73M, negative for the stored period.
  • The balance sheet shows USD 132.59M of cash versus USD 26.7M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -171.4% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -114.5% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 105.89M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ANL

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ANL fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ANL likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ANL to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of ANL's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research ANL

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.